Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05579366 · ClinicalTrials.gov registry record · Phase 1

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

A Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, sponsored by Genmab.

Recruiting
Registry status
Phase 1
Development phase
764
Enrollment target
20
Study locations

NCT05579366 is a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer that is actively recruiting participants, run by Genmab. The registered enrollment target is 764 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05579366, a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Genmab.

RECRUITING
Registry status
Phase 1
Development phase
764 participants
Enrollment target
20
Study locations

Study Summary

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Conditions Studied

Non-Small Cell Lung Cancer Endometrial Cancer Triple Negative Breast Cancer Fallopian Tube Cancer Mesothelioma Primary Peritoneal Carcinoma Breast Adenocarcinoma High-grade Serous Ovarian Cancer High Grade Epithelial Ovarian Cancer Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG Pembrolizumab
  • DRUG Bevacizumab
  • DRUG Carboplatin
  • DRUG Rina-S

Study Locations (20)

California

  • University of California Los Angeles Medical Center - Los Angeles
  • University of California, San Diego; Moores Cancer Center - San Diego
  • USOR Sansum Clinic - Santa Barbara
  • Providence Medical Foundation - Santa Rosa

Florida

  • USOR Florida Cancer Specialists South - Fort Myers
  • USOR Florida Cancer Specialists North - St. Petersburg
  • USOR Florida Cancer Specialists East - West Palm Beach

Arizona

  • USOR HonorHealth - Phoenix
  • USOR Arizona Oncology Associates - Tucson

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Institute - Detroit
  • START Midwest - Grand Rapids

Georgia

  • Augusta University Georgia Cancer Center - Augusta

Kansas

  • University of Kansas Medical Center (KUMC) - Westwood

Maryland

  • USOR Maryland Oncology Hematology - Rockville

Trial Details

FieldValue
Enrollment Target 764 participants
Start Date 2022-12-07
Est. Completion 2027-10
Phase Phase 1

Sponsor

Genmab

45 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05579366

The ClinicalTrials.gov registry entry for NCT05579366 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 764 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (16% higher). The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05579366 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT05579366 about?

NCT05579366 is a clinical study titled "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)". This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

What is the current status of trial NCT05579366?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 764 participants. The study started on 2022-12-07. Estimated completion is 2027-10.

What conditions does trial NCT05579366 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Fallopian Tube Cancer, Mesothelioma.

What interventions are being tested in trial NCT05579366?

The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Rina-S (DRUG).

Who is sponsoring clinical trial NCT05579366?

This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05579366 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Endometrial Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.